We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hemorrhagic Fever Viruses Could Be Bioweapons

By Biotechdaily staff writers
Posted on 27 May 2002
Hemorrhagic fever viruses such as Ebola, Marburg, and Lassa could be used as biologic weapons, according to a report from a panel of experts convened by the Center for Civilian Biodefense Strategies at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA). The panel's consensus statement was published in the May 8, 2002, issue of the Journal of the American Medical Association (JAMA).

Hemorrhagic fever viruses are considered "Category A” biologic weapons agents by the US Centers for Disease Control and Prevention (CDC) because they have the potential to cause widespread illness and death. The panel's report focused on eight viruses: Ebola, Marburg, Lassa fever, New World Arenavirus, Rift Valley fever, yellow fever, Ornsk hemorrhagic fever, and Kyasanur Forest disease. Ebola and Marburg are among the most deadly of these. Ebola kills 50-90% of those infected, and Marburg is fatal in 23-70% of cases.

There are no widely available diagnostic tests for these viruses, and few effective therapies or vaccines are available to treat them. The panel says strict infection controls need to be used during an outbreak, since many of the viruses can be spread by person-to-person contact. Patients should be isolated, and clinicians should wear protective gear.

"The Working Group's consensus recommends improvement to our diagnostic capacity and the development of a rapid test for diagnosing hemorrhagic fever viruses,” said Luciana Borio, M.D., lead author and a fellow at the Hopkins Center for Civilian Biodefense Strategies. "Research efforts should also focus on new antiviral medications, vaccines, and a more fundamental scientific study of the viruses that cause hemorrhagic illness.”




Related Links:
Center for Civilian Biodefense
JAMA

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10

Latest BioResearch News

Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
27 May 2002  |   BioResearch

Population-Scale Proteomics Study Identifies New Genetic-Protein Links
27 May 2002  |   BioResearch

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
27 May 2002  |   BioResearch